Acorda Therapeutics Inc (ACOR.OQ)
19 Jan 2018
Acorda Therapeutics is exploring a sale of the company, the Wall Street Journal reported, citing people familiar with the matter.
* ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES Source text - http://on.wsj.com/2Ay49BA Further company coverage: (Bengaluru Newsroom)
* ACORDA RESUBMITS NEW DRUG APPLICATION FOR INBRIJA™ (CVT-301, LEVODOPA INHALATION POWDER)
Acorda Therapeutics Inc said on Monday it would stop developing its Parkinson's disease drug, tozadenant, less than a week after the company reported deaths in key studies testing the treatment.
Nov 20 Acorda Therapeutics Inc said on Monday it would terminate developing its drug to treat Parkinson's disease, a week after the drugmaker reported five deaths in key studies testing the treatment.
* Acorda announces royalty monetization transactions for $53 million
Acorda Therapeutics Inc said five people died in trials for its Parkinson's disease drug, the latest in a series of setbacks for the drugmaker, sending its shares down 38 percent.
Nov 15 Acorda Therapeutics Inc's shares plunged 34 percent on Wednesday after the drugmaker said it had paused enrolling patients in two key trials testing its Parkinson's disease drug following patient deaths.
* Identified cases of agranulocytosis, possibly drug-related, in some cases associated with sepsis and death
Nov 15 Acorda Therapeutics Inc said on Wednesday it has halted enroling patients in a late-stage trial testing its drug to treat Parkinson's disease, after reports of cases related to neutropenia, sepsis and death.
|Novartis AG (NOVN.S)||CHF83.38||+0.48|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||7,000.00||-261.00|
|Merck KGaA (MRCG.DE)||€89.66||-0.46|
|Biogen Inc (BIIB.OQ)||$342.41||-2.03|
|BioMarin Pharmaceutical Inc. (BMRN.OQ)||$89.12||-0.66|
|Catalyst Pharmaceuticals Inc (CPRX.OQ)||$3.75||-0.04|
|Elango Industries Ltd (ELAN.BO)||Rs4.40||--|
|Sanofi SA (SASY.PA)||€72.95||+0.58|